Apontis Pharma Past Earnings Performance

Past criteria checks 0/6

Apontis PharmaDie Erträge des Sektors -32% sind im Durchschnitt pro Jahr zurückgegangen, während die Erträge des Sektors Pharmaceuticals growing auf 10.4% pro Jahr stiegen. Die Einnahmen sind growing mit einer durchschnittlichen Rate von 8.8% pro Jahr gesunken.

Key information

-32.0%

Earnings growth rate

-58.3%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate8.3%
Return on equity-37.3%
Net Margin-30.6%
Next Earnings Update08 May 2024

Recent past performance updates

Apontis Pharma's (ETR:APPH) Robust Earnings Are Supported By Other Strong Factors

Apr 08
Apontis Pharma's (ETR:APPH) Robust Earnings Are Supported By Other Strong Factors

Recent updates

We Think Apontis Pharma (ETR:APPH) Can Afford To Drive Business Growth

Dec 02
We Think Apontis Pharma (ETR:APPH) Can Afford To Drive Business Growth

Not Many Are Piling Into Apontis Pharma AG (ETR:APPH) Stock Yet As It Plummets 27%

Jul 29
Not Many Are Piling Into Apontis Pharma AG (ETR:APPH) Stock Yet As It Plummets 27%

Apontis Pharma's (ETR:APPH) Robust Earnings Are Supported By Other Strong Factors

Apr 08
Apontis Pharma's (ETR:APPH) Robust Earnings Are Supported By Other Strong Factors

Revenue & Expenses Breakdown
Beta

How Apontis Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

XTRA:APPH Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2337-11210
30 Sep 2342-7210
30 Jun 2346-3200
31 Mar 23510200
31 Dec 22563200
30 Sep 22563190
30 Jun 22564170
31 Mar 22542180
31 Dec 2151-1200
30 Sep 2148-1210
30 Jun 2146-1220
31 Mar 2142-1200
31 Dec 2039-1180
31 Dec 1940-2190
31 Dec 1820080

Qualität der Erträge: APPH ist derzeit unrentabel.

Wachsende Gewinnspanne: APPH ist derzeit unrentabel.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Ergebnisentwicklung: APPH ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 32% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von APPH verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: APPH ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Pharmaceuticals (2.8%) erschwert.


Return on Equity

Hohe Eigenkapitalrendite: APPH hat eine negative Eigenkapitalrendite (-8.37%), da es derzeit unrentabel ist.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.